2:39 PM
 | 
Apr 05, 2019
 |  BC Extra  |  Company News

Gilead sees Descovy as successor to Truvada for HIV PrEP

With Truvada’s patent expiration imminent, Gilead is looking to Descovy to extend its hold on the HIV prevention market.

Gilead Sciences Inc. (NASDAQ:GILD) said Friday it submitted an sNDA to FDA for Descovy emtricitabine/tenofovir alafenamide for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. The company's Truvada...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >